Commentary
Podcast
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2
Author(s):
In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more.
Today we are bringing you part 2 of a 2-part podcast series on opportunities for biosimilars, specifically adalimumab biosimilars, in dermatology, gastroenterology, and rheumatology.
The discussion was moderated by Ryan Haumschild, PharmD, director of Pharmacy Services at Emory Healthcare and Winship Cancer Institute. The topics of conversation for today’s podcast include implementation of biosimilars in patients with no history of reference biologic use, insights on switching patients from the reference to the biosimilar, auto-substitution, impact of biosimilar utilization on payers and pharmacy benefit managers, and more.
In part 1, the panel discussed provider and payer considerations for transitioning patients to biosimliars, challenges associated with biosimilars, approaches to prescribing biosimilars over reference products, and more
Listen above or through one of these podcast services:
